Similar articles

• [In-vitro change in CFU-GM in chronic myeloid leukemia and myelodysplastic syndromes. Its implication in the dysfunction of the hematologic barrier].

  Gronda M, Malka A, Demattei A, Elizalde P, Santarelli MT, Bianchi de Di Risio CC. Gronda M, et al. Sangre (Barc). 1988 Aug;33(4):277-81. Sangre (Barc). 1988. PMID: 3187844 Spanish. No abstract available.
• [Functional characteristics of hematopoietic and stromal cells in various forms of myelodysplastic syndrome].

  Gerasimova LP, Manakova TE, Tsvetaeva NV, Lukina EA, Kozlovskaia AS. Gerasimova LP, et al. Biull Eksp Biol Med. 1999 Jan;127(1):14-8. Biull Eksp Biol Med. 1999. PMID: 10189996 Russian. No abstract available.
• [Histopathology and morphometry of hematopoiesis in bone marrow of AIDS patients in comparison with patients with myelodysplastic syndrome].

  Kaloutsi V, Maschek H, Kohlmeyer U, Nafe R, Choritz H, Amor A, Georgii A. Kaloutsi V, et al. Verh Dtsch Ges Pathol. 1991;75:131-5. Verh Dtsch Ges Pathol. 1991. PMID: 1724815 German.
• [Primary myelodysplastic syndromes].

  Brohée D. Brohée D. Rev Med Brux. 1988 Sep;9(6):327-33. Rev Med Brux. 1988. PMID: 3051250 Review. French. No abstract available.
• [Myelodysplastic syndromes].

  Raza A, Vadhan-Raj S, Chávez-Sánchez G. Raza A, et al. Rev Invest Clin. 1997 May;49 Suppl 1:15-21. Rev Invest Clin. 1997. PMID: 9380984 Review. Spanish. No abstract available.